EUCTR2005-001132-72-IT进行中（未招募）不适用
A Phase 2 Study of combined modality treatment with primary chemotherapy followed by endoscopic laser resection in intermediate stage laryngeal squamous cell carcinoma.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
尚未招募
不适用
Phase I and II trial of combination therapy using nab-Paclitaxel+Pertuzumab+Trastuzumab for HER2 positive metastatic breast cancermetastatic breast cancerJPRN-UMIN000035869The University of Tokushima Graduate School, Depertment of Thoracic, Endocrine surgery and Oncology, Institute of Health Bioscience30
已完成
2 期
Phase II study comparing combination therapy with carboplatin plus pemetrexed vs combination therapy with pemetrexed plus bevacizumab in chemo-naive elderly patients with advanced non-squamous non-small-cell lung cancer (HSR1402).advanced non-squamous non-small-cell lung cancerJPRN-UMIN000014302Hamamatsu Univ. School of Medicine64
招募中
2 期
A randomised phase II trial of combined therapy with CPT-11/CDDP versus CPT-11 alone in second-line treatment of advaneced or recurrent gastric cancer resistant to Docetaxel/Cisplatin/TS-1 (DCS) therapyGastric CancerJPRN-UMIN000003141Sapporo Medical University School of Medicine Dept. of Internal Medicine(4)80
进行中（未招募）
2 期
A phase II study for HER2 amplified advanced solid tumors (JUPITER trial)Solid tumorsHER2, solid tumorD009369JPRN-jRCT2031180150Ikeda Sadakatsu38
已完成
1 期
Phase I/II study on combination therapy consisting of a fixed dose-rate infusion of gemcitabine with oral fluorinated pyrimidine compound S-1 (FGS) in patients with gemcitabine-refractory advanced pancreatic cancerPatients with gemcitabine-refractory metastatic pancreatic cancerJPRN-C000000450ational Cancer Center Hospital, Hepatobiliary and Pancreatic Oncology Division40